MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR) Upgraded at Zacks I

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday. The firm presently has a $27.00 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 12.45% from the company’s previous close.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Get MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 alerts:

Separately, Deutsche Bank upgraded MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 from a “hold” rating to a “buy” rating in a report on Monday, December 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has an average rating of “Buy” and a consensus target price of $34.25.

NYSEARCA MOR opened at $24.01 on Friday. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a 1 year low of $21.75 and a 1 year high of $35.90.

Featured Story: How to find the components of the quick ratio

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com